Nunzia Pharmaceutical Corporation is a pharmaceutical company. The Company focuses on development and delivery of pharmaceutical and nutraceutical-based therapies for the behavioral symptoms of Autistic Spectrum of Disorders (ASDs) and related conditions, such as Fragile X syndrome, as well as common anxiety-based disorders. The Company has developed NUNZIA, which is a combination of 16 vitamins, minerals and herbs which directly focuses and targets the hippocampus area of the brain, where all anxiety-based disorders originate.

Employees

Sector

Pharmaceuticals

More about the company

Market Closed - OTC Markets 18:34:37 24/12/2025 +04			5-day change	1st Jan Change
0.000100 ^USD	-.--%		-.--%	-

14/11/22	Nunzia Pharmaceutical Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
03/10/22	Nunzia Pharmaceutical Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI

Market Cap	34.76M 31.18M 28.49M 26.01M 49M 3.27B 50.55M 343M 137M 1.74B 130M 128M 5.5B	P/E 2020	-94.8x	P/E 2021	-2.54x
Enterprise Value	34.86M 31.26M 28.57M 26.08M 49.14M 3.28B 50.69M 344M 137M 1.75B 131M 128M 5.52B	EV / Sales 2020	-	EV / Sales 2021	-
Free-Float	18.04%	Yield 2020 *	-	Yield 2021	-

14/11/22	Nunzia Pharmaceutical Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
03/10/22	Nunzia Pharmaceutical Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
23/05/22	Nunzia Pharmaceutical Company Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
15/04/22	Nunzia Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	CI
15/04/22	Nunzia Pharmaceutical Company Auditor Raises 'Going Concern' Doubt	CI
29/03/22	Nunzia Pharmaceutical Company Auditor Raises 'Going Concern' Doubt	CI
10/11/21	Nunzia Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
16/09/21	Nunzia Pharmaceutical Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	CI
16/08/21	Nunzia Pharmaceutical Corporation Announces Offering of Patented Blood Warmer Through Medical Supply Division	CI
06/08/21	Nunzia Pharmaceutical Corporation Signs A Licensing Agreement with Michael Mitsunaga	CI
25/06/21	Global WholeHealth Partners Corporation acquired distribution and selling rights of Moderna Vaccine of Nunzia Pharmaceutical Corporation.	CI
16/06/21	Global Wholehealth Partners Corporation Partners with Nunzia Pharmaceutical Inc. to Distribute and Sell the Pfizer-BioNTech COVID-19 Vaccine	CI
10/06/21	Global Wholehealth Partners Corporation Grants the Rights from Nunzia Pharmaceutical Inc. to Distribute and Sell the Johnson & Johnson Covid-19 Vaccine	CI

14/11/22	NUNZIA PHARMACEUTICAL CO Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
03/10/22	NUNZIA PHARMACEUTICAL CO Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
23/05/22	NUNZIA PHARMACEUTICAL CO Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
15/04/22	NUNZIA PHARMACEUTICAL CO MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
29/03/22	NUNZIA PHARMACEUTICAL CO Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q/A)	AQ

Nunzia Pharmaceutical Company Stock

Stocks

NUNZ

US67097W1027

Pharmaceuticals

Valuation: Nunzia Pharmaceutical Company

Chart: Nunzia Pharmaceutical Company

Latest news: Nunzia Pharmaceutical Company

Press Releases: Nunzia Pharmaceutical Company

Price Extremes

Managers and Directors: Nunzia Pharmaceutical Company

Other Pharmaceuticals

Financials

Company Profile

1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		2.43
10 years	0		331.65

Manager	Title	Age	Since
Sara Gonzales CEO	Chief Executive Officer	53	-
Michael Mitsunaga CEO	Chief Executive Officer	70	01/01/2009
Shujie Cui CTO	Chief Tech/Sci/R&D Officer	64	05/12/2019

Director	Title	Age	Since
Michael Mitsunaga BRD	Director/Board Member	70	01/01/2009
Sara Gonzales BRD	Director/Board Member	53	-
Shujie Cui BRD	Director/Board Member	64	05/12/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NUNZIA PHARMACEUTICAL COMPANY	-.--%	-.--%	+9,900.00%	-96.67%	43.45K
ELI LILLY AND COMPANY	-0.79%	-4.48%	+46.48%	+125.69%	1,206B
JOHNSON & JOHNSON	+1.43%	+1.11%	+48.05%	+83.05%	665B
ABBVIE INC.	+1.07%	-1.21%	+32.92%	+104.92%	515B
ROCHE HOLDING AG	-0.36%	-3.25%	+45.42%	+65.10%	381B
MERCK & CO., INC.	-0.14%	-1.87%	+70.06%	+41.09%	362B
NOVARTIS AG	-0.78%	-0.52%	+30.47%	+58.09%	307B
ASTRAZENECA PLC	-0.80%	-0.21%	+7.98%	+36.17%	289B
AMGEN INC.	+0.03%	-1.20%	+43.79%	+69.83%	249B
GILEAD SCIENCES, INC.	-0.41%	-2.22%	+40.43%	+107.03%	207B
Average	-0.08%	-1.38%	+1,026.56%	+59.43%	417.97B
Weighted average by Cap.	-0.04%	-1.96%	+42.71%	+88.11%

	2020	2021
Net sales	-	-
Net income	-9.02M -8.09M -7.39M -6.75M -12.71M -848M -13.11M -89.08M -35.52M -452M -33.84M -33.12M -1.43B	-78.06M -70.01M -63.99M -58.41M -110M -7.34B -114M -771M -308M -3.92B -293M -287M -12.36B
Net Debt	-	97.31K 87.28K 79.77K 72.81K 137K 9.15M 142K 961K 383K 4.88M 365K 357K 15.41M